Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07413666

A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years

A Safety, Tolerability, Pharmacokinetic, Food Effect, and Proof-of-Concept Study of Single and Multiple Doses of ORX489 in Healthy Adults

Status
Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
212 (estimated)
Sponsor
Centessa Pharmaceuticals (UK) Limited · Industry
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.

Conditions

Interventions

TypeNameDescription
DRUGORX489 TabletsORX489 Tablets
OTHERPlacebo TabletsPlacebo Tablets

Timeline

Start date
2026-02-25
Primary completion
2027-06-30
Completion
2027-06-30
First posted
2026-02-17
Last updated
2026-02-25

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT07413666. Inclusion in this directory is not an endorsement.

A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years (NCT07413666) · Clinical Trials Directory